What one share of AN2 Therapeutics holds
We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases.
AN2 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.04 |
|---|---|
| Cash and investments | $1.22 |
| Book value | $2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$10.64 | — | — | — | −$17.36 |
| 2022 | — | −$2.79 | — | — | — | $4.92 |
| 2023 | — | −$2.74 | — | — | — | $4.19 |
| 2024 | — | −$1.72 | — | — | — | $2.74 |
| 2025 | — | −$1.16 | — | — | — | $1.94 |
Common questions about AN2 Therapeutics
How much does one share of AN2 Therapeutics earn?
Over the last 12 months, AN2 Therapeutics lost $1.04 for each share.
Does AN2 Therapeutics pay a dividend?
AN2 Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is AN2 Therapeutics’s book value per share?
AN2 Therapeutics’s book value is $2.09 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of AN2 Therapeutics have?
Each share of AN2 Therapeutics has $1.22 of cash and investments, as of June 30, 2026.
Has AN2 Therapeutics bought back shares?
AN2 Therapeutics’s share count rose about 1045% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.